Drug Trial Radar · NCT03948646
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Last checked: Nov 20, 2026Latest source record: May 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
351
Actual
Start
Dec 4, 2020
Primary completion
Aug 13, 2021
Study completion Aug 13, 2021
Sponsor
- Lead sponsor
- Botanix PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands. Current therapies have limited effectiveness, significant side effects, and can be invasive and costly. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis. This Phase 3 study will assess the safety and efficacy of sofpironium bromide, 15% gel versus vehicle (2 treatment arms), applied for the treatment of axillary hyperhidrosis.
Conditions
- Axillary Hyperhidrosis
Interventions
Sofpironium Bromide, 15%Drug
Active
VehicleDrug
Vehicle gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity Measure-Axillary-7 Item Total Score From Baseline to End of TreatmentTime frame: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.
- Observed Change in Participant (Vehicle Arm vs SB Gel 15% Arm) Ranked Gravimetric Sweat Production From Baseline to End of TreatmentTime frame: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.
Locations
42 sites in 1 country. Site status is shown where the registry gives one.
Cahaba Dermatology Skin & Health Center
Birmingham, Alabama
Advanced Research Associates
Glendale, Arizona
Arkansas Research Trials
North Little Rock, Arkansas
First OC Dermatology
Fountain Valley, California
CoDerm Research
Centennial, Colorado
Colorado Medical Research Center
Denver, Colorado
CCD Research, PLLC
Cromwell, Connecticut
The GW Medical Faculty Associates
Washington D.C., District of Columbia
Driven Research, LLC
Coral Gables, Florida
Florida Academic Dermatology Centers Research & Education, LLC
Coral Gables, Florida
GSI Clinical Research
Margate, Florida
Cordova Research Institute
Miami, Florida
MOORE Clinical Research, Inc.
Tampa, Florida
Advanced Medical Research PC
Sandy Springs, Georgia
DeNova Research
Chicago, Illinois
Qualmedica Research, LLC
Evansville, Indiana
Heartland Research Asssociates - AMR Company
Wichita, Kansas
Delricht Research
Baton Rouge, Louisiana
DelRicht Research
New Orleans, Louisiana
Lupo Center for Aesthetic and General Dermatology
New Orleans, Louisiana
Etre, Cosmetic Dermatology and Laser Center
New Orleans, Louisiana
DermAssociates
Rockville, Maryland
Bay State Clinical Trials, Inc.
Watertown, Massachusetts
Michigan Center for Skin Care Research
Clinton Township, Michigan
Hamzavi Dermatology, Inc.
Fort Gratiot, Michigan
Saint Louis University, Department of Dermatology
St Louis, Missouri
Meridian Clinical Research, LLC
Omaha, Nebraska
JDR Dermatology Research
Las Vegas, Nevada
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
SkinSearch of Rochester
Rochester, New York
Dermatology, Laser and Vein Specialists of the Carolinas
Charlotte, North Carolina
Aventiv Research Inc.
Dublin, Ohio
Yardley Dermatology Associates, PC
Morrisville, Pennsylvania
Westlake Dermatology & Cosmetic Surgery
Austin, Texas
Bellaire Dermatology Associates
Bellaire, Texas
J&S Studies, Inc.
College Station, Texas
Modern Research Associates
Dallas, Texas
University of Texas Health Science Center at Houston
Houston, Texas
Suzanne Bruce and Associates, P.A.
Houston, Texas
Dermatology Clinical Research Center of San Antonio
San Antonio, Texas
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.